Skip to content
Screener

Baxter International BAX Healthcare Systems & Technologies — Cost of Sales

Other segment segments

Medical Products & Therapies
$781M+12.5%
Pharmaceuticals
$458M+15.7%

Similar metrics at other companies

Enpro logo
NPOSealing Technologies — Cost of Sales
$103.3M+13.6%
Flotek Industries logo
FTKChemistry Technologies — Cost of Sales
$68.42M+63.9%
Teledyne Technologies logo
TDYEngineered Systems — Cost of Sales
$97.6M+6.6%
Phinia logo
PHINFuel Systems — Cost of Sales
$499M+2.5%
Lear Corporation logo
LEAE-Systems — Cost of Sales
$1.38B0.0%
Aptiv logo
APTVIntelligent Systems — Cost of Sales
-$1.18B-1.6%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.13B+22.3%
Enterprise value$12.33B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
(in millions)Three Months Ended March 31, 2026 / Medical Products & TherapiesThree Months Ended March 31, 2026 / Healthcare Systems & TechnologiesThree Months Ended March 31, 2026 / PharmaceuticalsThree Months Ended March 31, 2025 / Medical Products & TherapiesThree Months Ended March 31, 2025 / Healthcare Systems & TechnologiesThree Months Ended March 31, 2025 / Pharmaceuticals
Net sales$1,285$705$621$1,262$704$581
Cost of sales781390458694356396
Selling, general and administrative expenses290209102286217103
Research and development expenses544922594526
Other segment items(26)(9)(7)(21)(7)(7)
Segment operating income$186$66$46$244$93$63

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's healthcare systems & technologies — cost of sales?
Baxter International (BAX) reported healthcare systems & technologies — cost of sales of $390M in Q1 2026.
How has Baxter International's healthcare systems & technologies — cost of sales changed year-over-year?
Baxter International's healthcare systems & technologies — cost of sales increased by 9.6% year-over-year, from $356M to $390M.
What is the long-term trend for Baxter International's healthcare systems & technologies — cost of sales?
Over 3 years (2022 to 2025), Baxter International's healthcare systems & technologies — cost of sales has grown at a 3.1% compound annual growth rate (CAGR), from $1.46B to $1.6B.
What does healthcare systems & technologies — cost of sales mean?
Includes the direct costs associated with manufacturing and delivering the medical equipment and digital solutions sold by the segment. This encompasses raw materials, direct labor, and manufacturing overheads.

Ask your AI about Baxter International's healthcare systems & technologies — cost of sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude